31 October 2022
Appendix 3Y
28 October 2022
2022 SPL Notice of AGM and Proxy Form
27 October 2022
Appendix 2A
27 October 2022
Appendix 2A
27 October 2022
Appendix 3G
26 October 2022
Quarterly Activities Report & Appendix 4C
21 October 2022
VIRALEZE™ distribution agreement for Hong Kong and Macau
21 October 2022
Change in Substantial Holder
7 October 2022
Appendix 3Y
7 October 2022
Appendix 3H
5 October 2022
Board Renewal
30 September 2022
Starpharma Date of 2022 AGM
15 September 2022
Starpharma to present at Life Sciences Investor Forum
12 September 2022
Change in Substantial Holder - Allan Gray
12 September 2022
Change in Director's Interest Notice - J Fairley
12 September 2022
Starpharma presents promising additional clinical data for DEP® cabazitaxel in prostate cancer
2 September 2022
S&P DJI Announces September 2022 Quarterly Rebalance
25 August 2022
Starpharma annual report and full year financial results
25 August 2022
Appendix 4G – Corporate Governance Statement
10 August 2022
Starpharma signs new DEP® agreement with MSD

Investor Relations

For general questions about Starpharma Holdings Limited, please contact us at:

T: +61 3 8532 2700
E: investor.relations@starpharma.com


This website is intended for people seeking information about Starpharma for investment and business purposes. This website contains information about products that may not be available, or approved, in all countries, or may be available under different trademarks, or for different indications. Individuals seeking information about a Starpharma product should visit the relevant product website in their country of residence or consult a healthcare provider. Nothing contained on this site should be considered a solicitation, promotion, or advertisement for any product, including those under development. Any information on this site is not intended to provide medical advice nor should be used as a substitute for the advice provided by a doctor or other healthcare provider.